OTLK — Outlook Therapeutics Share News
0.000.00%
Last trade - 00:00- $126.42m
- $133.41m
- $1.41m
Brief: Outlook Therapeutics Submits Type A Meeting Request To FDA Following Complete Response Letter
Brief: Outlook Therapeutics Appoints Laura Cantrell As Vice President Of Corporate Strategy
U.S. STOCKS ON THE MOVE-Ulta Beauty and Berkshire Hathaway
U.S. STOCKS ON THE MOVE-Rivian, Tesla, MGM Resorts
U.S. STOCKS ON THE MOVE-Micron, Ironwood Pharmaceuticals, Chipotle Mexican Grill
U.S. STOCKS ON THE MOVE-Silver and gold miners, Baidu, Outlook Therapeutics
Outlook Therapeutics plunges after FDA rejects eye drug for third time
Brief: Outlook Therapeutics Provides Regulatory Update On U.S. FDA Review Of Lytenava
Outlook Therapeutics slides after US FDA declines its eye disease drug
NASDAQ RESUMED AT 04:35 PM
US FDA declines to approve Outlook Therapeutics' eye disease drug (updated)
US FDA declines to approve Outlook Therapeutics' eye disease drug
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:10 PM
Brief: Outlook Therapeutics Reports Financial Results For Fiscal Year 2025
Brief: Outlook Therapeutics FY EPS USD -1.79
Brief: Outlook Therapeutics Provides Update On Type A Meeting With FDA
U.S. RESEARCH ROUNDUP-Apple, GE Aerospace, Tesla
Brief: Outlook Therapeutics Requests Type A Meeting With FDA
U.S. STOCKS ON THE MOVE-SentinelOne, Autodesk, Dollar Tree